These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30425068)

  • 1. Timing of treatment of smoldering myeloma: early treatment.
    Mateos MV; González-Calle V
    Blood Adv; 2018 Nov; 2(21):3045-3049. PubMed ID: 30425068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of treatment of smoldering myeloma: delay until progression.
    Kumar SK
    Blood Adv; 2018 Nov; 2(21):3050-3053. PubMed ID: 30425069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent challenges with treating multiple myeloma early.
    Goodman AM; Kim MS; Prasad V
    Blood; 2021 Jan; 137(4):456-458. PubMed ID: 33236046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Advances in the Management of Smoldering Myeloma.
    Khan R; Zahid U; Kollu V; Jahan N; Ali M; Tricot G; Anwer F
    Am J Ther; 2020; 27(2):e194-e203. PubMed ID: 31842112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.
    Gran C; Luong V; Bruchfeld JB; Liwing J; Afram G; Lund J; Usmani S; Alici E; Nahi H
    Am J Hematol; 2021 Mar; 96(3):E63-E65. PubMed ID: 33264449
    [No Abstract]   [Full Text] [Related]  

  • 6. Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma.
    Atrash S; Robinson M; Slaughter D; Aneralla A; Brown T; Robinson J; Ndiaye A; Sprouse C; Zhang Q; Symanowski JT; Friend R; Voorhees PM; Usmani SZ; Bhutani M
    Blood Cancer J; 2018 Nov; 8(11):107. PubMed ID: 30410066
    [No Abstract]   [Full Text] [Related]  

  • 7. Ixazomib as treatment for pyoderma gangrenosum associated with IgA smoldering multiple myeloma.
    Cespedes DA; Gallitano SM; Bhutani D
    Ann Hematol; 2022 Feb; 101(2):441-442. PubMed ID: 33860355
    [No Abstract]   [Full Text] [Related]  

  • 8. The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact.
    Kunacheewa C; Manasanch EE
    Expert Rev Hematol; 2021 Dec; 14(12):1059-1069. PubMed ID: 34550841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pattern of the M-protein in smoldering myeloma over the time: an evolving risk factor.
    Fernández de Larrea C; Isola I; Pereira A; Cibeira MT; Bladé J; Rosiñol L
    Leukemia; 2018 Sep; 32(9):2082-2094. PubMed ID: 29795240
    [No Abstract]   [Full Text] [Related]  

  • 10. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.
    Fernández de Larrea C; Isola I; Pereira A; Cibeira MT; Magnano L; Tovar N; Rodríguez-Lobato LG; Calvo X; Aróstegui JI; Díaz T; Lozano E; Rozman M; Yagüe J; Bladé J; Rosiñol L
    Leukemia; 2018 Jun; 32(6):1427-1434. PubMed ID: 29463830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies in newly diagnosed and smoldering multiple myeloma: an updated review of current clinical evidence.
    Musto P; La Rocca F
    Expert Rev Hematol; 2020 May; 13(5):501-517. PubMed ID: 32290723
    [No Abstract]   [Full Text] [Related]  

  • 12. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
    Caers J; Fernández de Larrea C; Leleu X; Heusschen R; Zojer N; Decaux O; Kastritis E; Minnema M; Jurczyszyn A; Beguin Y; Wäsch R; Palumbo A; Dimopoulos M; Mateos MV; Ludwig H; Engelhardt M
    Oncologist; 2016 Mar; 21(3):333-42. PubMed ID: 26921288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
    Sundararajan S; Kumar A; Korde N; Agarwal A
    Curr Hematol Malig Rep; 2016 Apr; 11(2):102-10. PubMed ID: 26894382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timing treatment for smoldering myeloma: is earlier better?
    Hernández JÁ; Martínez-López J; Lahuerta JJ
    Expert Rev Hematol; 2019 May; 12(5):345-354. PubMed ID: 30907176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoldering Multiple Myeloma: Who and When to Treat.
    Mateos MV; González-Calle V
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression'.
    Lakshman A; Ravi P; Rajkumar SV; Kumar SK
    Leukemia; 2018 Sep; 32(9):2083-2085. PubMed ID: 29802327
    [No Abstract]   [Full Text] [Related]  

  • 17. Practical approach to the management of smoldering myeloma.
    Joseph NS; Lonial S
    Curr Opin Oncol; 2020 Nov; 32(6):656-663. PubMed ID: 32890022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?
    Fawole A; Abonour R; Stender M; Shatavi S; Gaikazian S; Anderson J; Jaiyesimi I
    Leuk Lymphoma; 2015 Jan; 56(1):34-41. PubMed ID: 24564573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Stratification and Treatment in Smoldering Multiple Myeloma.
    Lussier T; Schoebe N; Mai S
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
    Lakshman A; Rajkumar SV; Buadi FK; Binder M; Gertz MA; Lacy MQ; Dispenzieri A; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
    Blood Cancer J; 2018 Jun; 8(6):59. PubMed ID: 29895887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.